Volition opens a new Research and Development facility in Belgium with a state of the art, purpose-built laboratory
VolitionRx Appoints David Vanston as Chief Financial Officer
Volition America, Inc. Retains Strategic Expert in Securing Non-Dilutive Funding Opportunities in the United States
VolitionRx Limited Announces the Formation of Volition America, Inc.
VolitionRx Limited Celebrates CE Mark Announcement By Ringing Closing Bell at the New York Stock Exchange
VolitionRx Limited to Ring the New York Stock Exchange Closing Bell on Monday, March 13th at 4 pm Eastern Daylight Time
VolitionRx Limited Announces Full Fiscal Year 2016 Financial Results and Business Update
VolitionRx Limited to Present at the 29th Annual ROTH Conference
VolitionRx Limited Schedules Fourth Quarter and Full Year 2016 Earnings Conference Call and Business Update
A Logistics and Pathway Design Study for Volition's CE Marked NuQ(TM) Triage Test has been Commenced in the Capital Region of Denmark
